Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Advanced (unresectable and/or metastatic) soft tissue sarcoma Clinical criteria: Treatment Phase: Initial treatment Patient must have a WHO performance status of 2 or less, AND Patient must have received prior chemotherapy treatment including an anthracycline, AND Patient must not have received prior treatment with an angiogenesis inhibitor, AND The treatment must be the sole PBS-subsidised therapy for this condition. Patient must not have any of the following conditions: adipocytic soft tissue sarcoma; gastrointestinal stromal tumour (GIST); rhabdomyosarcoma other than alveolar or pleomorphic; chondrosarcoma; osteosarcoma; Ewings tumour/primitive neuroectodermal tumour; dermofibromatosis sarcoma protuberans; inflammatory myofibroblastic sarcoma; malignant mesothelioma; mixed mesodermal tumour of the uterus.
Stage IV clear cell variant renal cell carcinoma (RCC) Clinical criteria: Treatment Phase: Continuing treatment beyond 3 months Patient must have received an initial authority prescription for this drug for this condition, AND Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST), AND The treatment must be the sole PBS-subsidised tyrosine kinase inhibitor therapy for this condition. A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug. PBS-subsidy does not apply to a patient who has progressive disease whilst on, or, who has recurrent disease following treatment with any of: (i) cabozantinib, (ii) pazopanib, (iii) sunitinib.
“Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of Vascular Endothelial Growth Factor Receptors (VEGFR)-1, -2, and -3, platelet-derived growth factor (PDGFR)- α and – β, and stem cell factor receptor (c -KIT), with IC50 values of 10, 30, 47, 71, 84 and 74 nM, respectively.”
“Pazopanib is eliminated slowly with mean half-life of 30.9 hours after administration of the recommended dose of 800 mg.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Results from in vitro studies demonstrated that the metabolism of pazopanib is mediated primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8.”